Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | MMP2 | P08253 | 2/20 | 0.59 |
| ▸ | MMP3 | P08254 | 2/20 | 0.59 |
| ▸ | MMP13 | P45452 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102068 | 0.90 | TSHR (0.67) | MAPTALDH1A1SMN1; SMN2KMT2ATSHR | |
| SCHEMBL3099774 | 0.88 | MAPT (0.78) | MAPTALDH1A1SMN1; SMN2KMT2ATSHR | |
| SCHEMBL3091221 | 0.88 | MAPT (0.78) | MAPTALDH1A1SMN1; SMN2KMT2ATSHR | |
| SCHEMBL3095197 | 0.87 | MAPT (0.81) | MAPTALDH1A1SMN1; SMN2KMT2ATSHR | |
| SCHEMBL3091199 | 0.87 | MAPT (0.81) | MAPTALDH1A1SMN1; SMN2KMT2ATSHR | |
| SCHEMBL3092235 | 0.86 | MAPT (0.74) | MAPTALDH1A1SMN1; SMN2KMT2ATSHR | |
| SCHEMBL3097829 | 0.86 | MAPT (0.70) | MAPTALDH1A1SMN1; SMN2KMT2ATSHR | |
| SCHEMBL3103488 | 0.85 | MAPT (0.69) | MAPTALDH1A1SMN1; SMN2KMT2ATSHR | |
| SCHEMBL19214267 | 0.83 | MAPT (0.79) | MAPTALDH1A1SMN1; SMN2KMT2ATSHR | |
| SCHEMBL3096165 | 0.82 | MAPT (0.62) | MAPTALDH1A1SMN1; SMN2KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604190-B2 | Hetero isonipecotic modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-10 | — | — | US | claimed |
| US-20100256359-A1 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | GAUL MICHEAL D | 2010-10-07 | — | — | US | claimed |
| EP-1768959-A2 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-04 | — | — | EP | claimed |
| WO-2006004793-A2 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2006-01-12 | — | — | WO | claimed |
| US-20050288281-A1 | Hetero isonipecotic modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-29 | — | — | US | claimed |
| US-8604190-B2 | Hetero isonipecotic modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-10 | — | — | US | disclosed |
| US-20100256359-A1 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | GAUL MICHEAL D | 2010-10-07 | — | — | US | disclosed |
| US-20100256359-A1 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | GAUL MICHEAL D | 2010-10-07 | — | — | US | disclosed |
| US-20100256359-A1 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | GAUL MICHEAL D | 2010-10-07 | — | — | US | disclosed |
| US-7622579-B2 | (1-o-Tolyl-piperidin-4-yl)-thiomorpholin-4-yl-methanone; useful for treating diseases and conditions selected from osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, sunburn, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-24 | — | — | US | disclosed |
| US-7622579-B2 | (1-o-Tolyl-piperidin-4-yl)-thiomorpholin-4-yl-methanone; useful for treating diseases and conditions selected from osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, sunburn, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-24 | — | — | US | disclosed |
| US-7622579-B2 | (1-o-Tolyl-piperidin-4-yl)-thiomorpholin-4-yl-methanone; useful for treating diseases and conditions selected from osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, sunburn, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-24 | — | — | US | disclosed |
| US-20050288281-A1 | Hetero isonipecotic modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288281-A1 | Hetero isonipecotic modulators of vanilloid VR1 receptor | VDAC1, HVCN1, TRPV1 | MAPT 4524/4885ALDH1A1 1592/4885SMN1; SMN2 4542/4885 |
| US-20100256359-A1 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | VDAC1, HVCN1, TRPV1 | MAPT 4524/4885ALDH1A1 1592/4885SMN1; SMN2 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.